Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Xtant Medical Holdings (XTNT) Other financing activities (2018 - 2025)

Xtant Medical Holdings (XTNT) has disclosed Other financing activities for 6 consecutive years, with $15000.0 as the latest value for Q2 2025.

  • On a quarterly basis, Other financing activities fell 91.62% to $15000.0 in Q2 2025 year-over-year; TTM through Sep 2025 was $52000.0, a 92.67% decrease, with the full-year FY2024 number at $651000.0, up 172.38% from a year prior.
  • Other financing activities was $15000.0 for Q2 2025 at Xtant Medical Holdings, down from $34000.0 in the prior quarter.
  • In the past five years, Other financing activities ranged from a high of $436000.0 in Q1 2024 to a low of $3000.0 in Q4 2024.
  • A 4-year average of $100555.6 and a median of $40000.0 in 2023 define the central range for Other financing activities.
  • Peak YoY movement for Other financing activities: surged 990.0% in 2024, then tumbled 92.2% in 2025.
  • Xtant Medical Holdings' Other financing activities stood at $104000.0 in 2021, then tumbled by 41.35% to $61000.0 in 2023, then crashed by 95.08% to $3000.0 in 2024, then soared by 400.0% to $15000.0 in 2025.
  • Per Business Quant, the three most recent readings for XTNT's Other financing activities are $15000.0 (Q2 2025), $34000.0 (Q1 2025), and $3000.0 (Q4 2024).